Substituted gamma-lactone compounds as NMDA-antagonists

Substituted γ-lactone compounds of the general formula I,

• 4
• in which
• R1 denotes an optionally at least mono-substituted aryl or heteroaryl residue, an optionally at least mono-substituted aryl or heteroaryl residue attached via a C1-6 alkylene group, an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C1-10 residue, an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C2-10 residue or an optionally at least mono-substituted, saturated or at least mono-unsaturated cycloaliphatic C3-8 residue,
• R2 denotes an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C 1-10 residue or an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C2-10 residue,
• R3 denotes an optionally at least mono-substituted aryl residue,
• R4 denotes H, or
• R3 and R4 together denote an optionally at least mono-substituted, saturated or at least mono-unsaturated aliphatic C3-7 residue, with the proviso that the residue R2 in this case denotes an optionally at least mono-substituted aryl residue, an optionally at least mono-substituted, saturated, branched or unbranched aliphatic C1-10 residue or an optionally at least mono-substituted, at least partially unsaturated, branched or unbranched aliphatic C2-10 residue
• in the form of the racemates, diastereomers or enantiomers thereof in the form of the base thereof or of a corresponding physiologically acceptable salt,
• wherein the compounds of the general formula I, in which R1 denotes a 2-, 4-, 6-trichlorophenyl or a tosyl residue, R2 a methyl residue, R3 a phenyl residue and R4 denotes H, are excepted.